Effect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial

Authors
Negah Chaabi Ahvazi 1
Simin Hemati 1
Mohamad Mohamadianpanah 2
1 Department of Radiotherapy and Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Colorectal Cancer Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
Background: Aprepitant is one of the effective antiemetic drugs that usually used for a period of 3 days for prevention of anthracycline/cyclophosphamide (AC) induced nausea and vomiting. However, many patients still experience nausea and vomiting on days 3–5. The aim of this study was to evaluate the effect of an increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving AC chemotherapy.
Materials and Methods: It was a randomized, crossover, controlled clinical trial. Women with breast cancer and scheduled to receive AC regimens were enrolled in this study. Enrolled patients were randomized into two groups. Group I received 3 days regimen of aprepitant in the first course of AC regimen chemotherapy and 6 days regimen of aprepitant in the second course; Group II received 6 days regimen followed by 3 days regimen. For nausea and vomiting assessment, we used Eastern Cooperative Oncology Group questionnaire.
Results: Forty-nine patients were enrolled in this study. Sixty-three percent achieved a complete response with 6 days aprepitant regimen compared with 39% with 3 days regimen (P < 0.001). Ten percent had at least one vomiting episode during the 6 days regimen versus 15% with 3 days regimen (P = 0.034). Nausea was significantly more severe in 3 days regimen of aprepitant than in 6 days regimen.
Conclusion: Increase in the duration of aprepitant consumption through 6 days resulted in significantly better prevention of nausea and vomiting than 3 days consumption for women receiving AC chemotherapy.

Keywords

1.
Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, et al. Chemotherapy-induced nausea and vomiting in clinical practice: Impact on patients' quality of life. Support Care Cancer 2012;20:3141-8.  Back to cited text no. 1
    
2.
Grunberg SM. Obstacles to the implementation of antiemetic guidelines. J Natl Compr Canc Netw 2009;7:601-5.  Back to cited text no. 2
    
3.
Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw 2007;5:51-9.  Back to cited text no. 3
    
4.
Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 2011;19:807-13.  Back to cited text no. 4
    
5.
Aapro M. Optimising antiemetic therapy: What are the problems and how can they be overcome? Curr Med Res Opin 2005;21:885-97.  Back to cited text no. 5
    
6.
Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94.  Back to cited text no. 6
    
7.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 2010;21 Suppl 5:v232-43.  Back to cited text no. 7
    
8.
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98.  Back to cited text no. 8
    
9.
Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): A comprehensive review. Ann Oncol 2015;26:1081-90.  Back to cited text no. 9
    
10.
Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J 2013;43:73-6.  Back to cited text no. 10
    
11.
Rey J, Launay-Vacher V, Scotté F, Krakowski I, Aapro M. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Oncologie 2012;14:329.  Back to cited text no. 11
    
12.
Chan A, Low XH, Yap KY. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm 2012;18:385-94.  Back to cited text no. 12
    
13.
American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24:2932-47.  Back to cited text no. 13
    
14.
Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-8.  Back to cited text no. 14
    
15.
Laumann AE, Derick AJ. Tattoos and body piercings in the United States: A national data set. J Am Acad Dermatol 2006;55:413-21.  Back to cited text no. 15
    
16.
Uchida M, Ikesue H, Kato K, Ichinose K, Hiraiwa H, Sakurai A, et al. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. Am J Health Syst Pharm 2013;70:343-9.  Back to cited text no. 16
    
17.
Aprepitant FDA Advisory Committee Background Package. Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3928B1_01_Merck%20. Backgrounder.pdf. [Last accessed on 2011 Dec 01].  Back to cited text no. 17
    
18.
Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer 2010;18:423-31.  Back to cited text no. 18
    
19.
Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, et al. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int 2015;2015:497597.  Back to cited text no. 19
    
20.
Badar T, Mattiuzzi G, Kantarjian HM, Ravandi F, Daver NG, Manero GG, et al. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron plus aprepitant for the prevention of nausea and vomiting in patients (Pts) with hematological malignancies receiving regimens containing high dose cytarabine. Blood 2013;122:3887.  Back to cited text no. 20
    
21.
Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.  Back to cited text no. 21
    
22.
Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: A hoosier oncology group study. J Clin Oncol 2012;30:3998-4003.  Back to cited text no. 22
    
23.
Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer 2013;21:565-73.  Back to cited text no. 23
    
24.
Hingmire S, Raut N. Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens. South Asian J Cancer 2015;4:7-10.  Back to cited text no. 24
    
25.
Madsen JL, Fuglsang S. A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. Aliment Pharmacol Ther 2008;27:609-15.  Back to cited text no. 25
    
26.
Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev 2013;39:113-7.  Back to cited text no. 26
    
27.
Stiff PJ, Fox-Geiman MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D, et al. Prevention of nausea and vomiting associated with stem cell transplant: Results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 2013;19:49-55.e1.  Back to cited text no. 27
    
28.
Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and fosaprepitant: A 10-year review of efficacy and safety. Oncologist 2015;20:450-8.  Back to cited text no. 28
    
29.
Nasu R, Nannya Y, Kurokawa M. A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies. Int J Hematol 2015;101:376-85.  Back to cited text no. 29
Advanced Biomedical Research
Volume 2015, october
October 2015
Pages 1-5